JPWO2022111621A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2022111621A5 JPWO2022111621A5 JP2023531615A JP2023531615A JPWO2022111621A5 JP WO2022111621 A5 JPWO2022111621 A5 JP WO2022111621A5 JP 2023531615 A JP2023531615 A JP 2023531615A JP 2023531615 A JP2023531615 A JP 2023531615A JP WO2022111621 A5 JPWO2022111621 A5 JP WO2022111621A5
- Authority
- JP
- Japan
- Prior art keywords
- optionally substituted
- pharma
- acceptable salt
- cancer
- ceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000003839 salts Chemical class 0.000 claims description 135
- 150000001875 compounds Chemical class 0.000 claims description 133
- 125000000217 alkyl group Chemical group 0.000 claims description 95
- 229910052731 fluorine Inorganic materials 0.000 claims description 90
- 125000001424 substituent group Chemical group 0.000 claims description 85
- 229910052739 hydrogen Inorganic materials 0.000 claims description 64
- 125000004404 heteroalkyl group Chemical group 0.000 claims description 60
- 125000000623 heterocyclic group Chemical group 0.000 claims description 56
- 239000001257 hydrogen Substances 0.000 claims description 53
- 150000002431 hydrogen Chemical class 0.000 claims description 46
- 125000005842 heteroatom Chemical group 0.000 claims description 37
- 229910052760 oxygen Inorganic materials 0.000 claims description 36
- 229910052717 sulfur Inorganic materials 0.000 claims description 35
- 125000004452 carbocyclyl group Chemical group 0.000 claims description 31
- 125000004043 oxo group Chemical group O=* 0.000 claims description 29
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 26
- 229910052799 carbon Inorganic materials 0.000 claims description 24
- 125000001072 heteroaryl group Chemical group 0.000 claims description 24
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims description 23
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 claims description 23
- 125000002947 alkylene group Chemical group 0.000 claims description 23
- 229910052805 deuterium Inorganic materials 0.000 claims description 23
- 206010006187 Breast cancer Diseases 0.000 claims description 22
- 206010028980 Neoplasm Diseases 0.000 claims description 21
- 201000011510 cancer Diseases 0.000 claims description 21
- 208000026310 Breast neoplasm Diseases 0.000 claims description 19
- 125000004429 atom Chemical group 0.000 claims description 18
- 229910052736 halogen Inorganic materials 0.000 claims description 18
- 150000002367 halogens Chemical class 0.000 claims description 18
- 238000000034 method Methods 0.000 claims description 11
- 229910052757 nitrogen Inorganic materials 0.000 claims description 11
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 claims description 7
- 125000003545 alkoxy group Chemical group 0.000 claims description 7
- 229910052801 chlorine Inorganic materials 0.000 claims description 7
- 206010033128 Ovarian cancer Diseases 0.000 claims description 6
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 6
- 208000003721 Triple Negative Breast Neoplasms Diseases 0.000 claims description 6
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 6
- 239000008194 pharmaceutical composition Substances 0.000 claims description 6
- 208000022679 triple-negative breast carcinoma Diseases 0.000 claims description 6
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 5
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 5
- 125000003342 alkenyl group Chemical group 0.000 claims description 5
- 125000000304 alkynyl group Chemical group 0.000 claims description 5
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 5
- 125000005549 heteroarylene group Chemical group 0.000 claims description 5
- 201000005202 lung cancer Diseases 0.000 claims description 5
- 208000020816 lung neoplasm Diseases 0.000 claims description 5
- 125000000843 phenylene group Chemical group C1(=C(C=CC=C1)*)* 0.000 claims description 5
- 102100037858 G1/S-specific cyclin-E1 Human genes 0.000 claims description 4
- 102100037854 G1/S-specific cyclin-E2 Human genes 0.000 claims description 4
- 101000738568 Homo sapiens G1/S-specific cyclin-E1 Proteins 0.000 claims description 4
- 101000738575 Homo sapiens G1/S-specific cyclin-E2 Proteins 0.000 claims description 4
- 230000003321 amplification Effects 0.000 claims description 4
- 229910052794 bromium Inorganic materials 0.000 claims description 4
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 4
- 230000002018 overexpression Effects 0.000 claims description 4
- 206010005003 Bladder cancer Diseases 0.000 claims description 3
- 206010055113 Breast cancer metastatic Diseases 0.000 claims description 3
- 206010009944 Colon cancer Diseases 0.000 claims description 3
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 3
- 108010025464 Cyclin-Dependent Kinase 4 Proteins 0.000 claims description 3
- 108010025468 Cyclin-Dependent Kinase 6 Proteins 0.000 claims description 3
- 102100036252 Cyclin-dependent kinase 4 Human genes 0.000 claims description 3
- 102100026804 Cyclin-dependent kinase 6 Human genes 0.000 claims description 3
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 3
- 208000017891 HER2 positive breast carcinoma Diseases 0.000 claims description 3
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims description 3
- 208000005726 Inflammatory Breast Neoplasms Diseases 0.000 claims description 3
- 206010021980 Inflammatory carcinoma of the breast Diseases 0.000 claims description 3
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 3
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 3
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 3
- 206010060862 Prostate cancer Diseases 0.000 claims description 3
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 3
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims description 3
- 206010038389 Renal cancer Diseases 0.000 claims description 3
- 208000024770 Thyroid neoplasm Diseases 0.000 claims description 3
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 3
- 208000002495 Uterine Neoplasms Diseases 0.000 claims description 3
- 238000009261 endocrine therapy Methods 0.000 claims description 3
- 229940034984 endocrine therapy antineoplastic and immunomodulating agent Drugs 0.000 claims description 3
- 201000004101 esophageal cancer Diseases 0.000 claims description 3
- 230000001747 exhibiting effect Effects 0.000 claims description 3
- 230000002496 gastric effect Effects 0.000 claims description 3
- 201000010536 head and neck cancer Diseases 0.000 claims description 3
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 3
- 201000004653 inflammatory breast carcinoma Diseases 0.000 claims description 3
- 230000005764 inhibitory process Effects 0.000 claims description 3
- 201000010982 kidney cancer Diseases 0.000 claims description 3
- 201000007270 liver cancer Diseases 0.000 claims description 3
- 208000014018 liver neoplasm Diseases 0.000 claims description 3
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 3
- 201000002528 pancreatic cancer Diseases 0.000 claims description 3
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 3
- 210000002784 stomach Anatomy 0.000 claims description 3
- 201000002510 thyroid cancer Diseases 0.000 claims description 3
- 229960000575 trastuzumab Drugs 0.000 claims description 3
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 3
- 206010046766 uterine cancer Diseases 0.000 claims description 3
- 125000004474 heteroalkylene group Chemical group 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims description 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims 3
- 229940127557 pharmaceutical product Drugs 0.000 claims 3
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 2
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 2
- 239000008177 pharmaceutical agent Substances 0.000 claims 2
- 125000000753 cycloalkyl group Chemical group 0.000 description 40
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 11
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 9
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 8
- -1 F or Cl) Chemical class 0.000 description 4
- 125000000956 methoxy group Chemical class [H]C([H])([H])O* 0.000 description 4
- 125000004433 nitrogen atom Chemical group N* 0.000 description 4
- 125000003003 spiro group Chemical group 0.000 description 4
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 3
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 3
- GAWIXWVDTYZWAW-UHFFFAOYSA-N C[CH]O Chemical group C[CH]O GAWIXWVDTYZWAW-UHFFFAOYSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
- 125000002950 monocyclic group Chemical group 0.000 description 2
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 1
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 1
- 206010041067 Small cell lung cancer Diseases 0.000 description 1
- DHXVGJBLRPWPCS-UHFFFAOYSA-N Tetrahydropyran Chemical compound C1CCOCC1 DHXVGJBLRPWPCS-UHFFFAOYSA-N 0.000 description 1
- 208000009956 adenocarcinoma Diseases 0.000 description 1
- HONIICLYMWZJFZ-UHFFFAOYSA-N azetidine Chemical compound C1CNC1 HONIICLYMWZJFZ-UHFFFAOYSA-N 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
- UHHKSVZZTYJVEG-UHFFFAOYSA-N oxepane Chemical compound C1CCCOCC1 UHHKSVZZTYJVEG-UHFFFAOYSA-N 0.000 description 1
- AHHWIHXENZJRFG-UHFFFAOYSA-N oxetane Chemical compound C1COC1 AHHWIHXENZJRFG-UHFFFAOYSA-N 0.000 description 1
- 125000003566 oxetanyl group Chemical group 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 206010041823 squamous cell carcinoma Diseases 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNPCT/CN2020/132454 | 2020-11-27 | ||
| CN2020132454 | 2020-11-27 | ||
| CNPCT/CN2021/081236 | 2021-03-17 | ||
| CN2021081236 | 2021-03-17 | ||
| PCT/CN2021/133429 WO2022111621A1 (en) | 2020-11-27 | 2021-11-26 | Aminoheteroaryl kinase inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024506116A JP2024506116A (ja) | 2024-02-09 |
| JP2024506116A5 JP2024506116A5 (https=) | 2024-12-04 |
| JPWO2022111621A5 true JPWO2022111621A5 (https=) | 2024-12-04 |
Family
ID=81753779
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023531615A Pending JP2024506116A (ja) | 2020-11-27 | 2021-11-26 | アミノヘテロアリールキナーゼ阻害剤 |
| JP2024531423A Pending JP2024541533A (ja) | 2020-11-27 | 2022-11-23 | アミノヘテロアリールキナーゼ阻害薬 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024531423A Pending JP2024541533A (ja) | 2020-11-27 | 2022-11-23 | アミノヘテロアリールキナーゼ阻害薬 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US20240166635A1 (https=) |
| EP (2) | EP4251613A4 (https=) |
| JP (2) | JP2024506116A (https=) |
| KR (1) | KR20230127228A (https=) |
| CN (2) | CN116528869B (https=) |
| AU (3) | AU2021385745C1 (https=) |
| CA (2) | CA3202990A1 (https=) |
| IL (1) | IL303237A (https=) |
| MX (1) | MX2024006300A (https=) |
| WO (2) | WO2022111621A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20230127228A (ko) * | 2020-11-27 | 2023-08-31 | 올오리온 테라퓨틱스 인크. | 아미노헤테로아릴 키나아제 억제제 |
| CA3207392A1 (en) * | 2021-02-05 | 2022-08-11 | Xiaoxia Yan | Cdk inhibitor |
| EP4532473A1 (en) * | 2022-05-27 | 2025-04-09 | Allorion Therapeutics Inc. | Aminoheteroaryl kinase inhibitors |
| EP4731620A1 (en) * | 2023-06-25 | 2026-04-29 | Allorion Therapeutics Inc | Isotopologues of aminoheteroaryl kinase inhibitors and uses thereof |
| WO2026024674A1 (en) | 2024-07-22 | 2026-01-29 | Genesis Therapeutics, Inc. | Methods of treating skp2-associated cancers |
| EP4725942A1 (en) * | 2024-10-09 | 2026-04-15 | Sibylla Biotech S.p.A. | Compounds active on cyclin d1 pathway and their use |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0004888D0 (en) * | 2000-03-01 | 2000-04-19 | Astrazeneca Uk Ltd | Chemical compounds |
| GB0004890D0 (en) * | 2000-03-01 | 2000-04-19 | Astrazeneca Uk Ltd | Chemical compounds |
| GB0016877D0 (en) * | 2000-07-11 | 2000-08-30 | Astrazeneca Ab | Chemical compounds |
| GB0021726D0 (en) * | 2000-09-05 | 2000-10-18 | Astrazeneca Ab | Chemical compounds |
| EP1343782B1 (en) * | 2000-12-21 | 2009-05-06 | SmithKline Beecham Corporation | Pyrimidineamines as angiogenesis modulators |
| KR100874791B1 (ko) * | 2001-05-29 | 2008-12-18 | 바이엘 쉐링 파마 악티엔게젤샤프트 | Ｃｄｋ-억제 피리미딘, 그의 제조방법 및 약제로서의 용도 |
| GB0113041D0 (en) * | 2001-05-30 | 2001-07-18 | Astrazeneca Ab | Chemical compounds |
| KR20040062557A (ko) * | 2001-11-01 | 2004-07-07 | 얀센 파마슈티카 엔.브이. | 글리코겐 신타제 키나제 3β 억제제로서의아미노벤즈아미드 유도체 |
| GB0205693D0 (en) * | 2002-03-09 | 2002-04-24 | Astrazeneca Ab | Chemical compounds |
| GB0205688D0 (en) * | 2002-03-09 | 2002-04-24 | Astrazeneca Ab | Chemical compounds |
| AU2003212282A1 (en) * | 2002-03-11 | 2003-09-22 | Schering Aktiengesellschaft | Cdk inhibiting 2-heteroaryl pyrimidine, the production thereof, and use thereof as a medicament |
| BR0316680A (pt) * | 2002-11-28 | 2005-10-18 | Schering Ag | Pirimidinas inibidoras de chk, pdk e akt, sua produção e uso como agentes farmacêuticos |
| US7504396B2 (en) * | 2003-06-24 | 2009-03-17 | Amgen Inc. | Substituted heterocyclic compounds and methods of use |
| DE102005008310A1 (de) * | 2005-02-17 | 2006-08-24 | Schering Ag | Verwendung von CDKII Inhibitoren zur Fertilitätskontrolle |
| WO2006122003A2 (en) * | 2005-05-05 | 2006-11-16 | Ardea Biosciences, Inc. | Diaryl-purine, azapurines and -deazapurines as non-nucleoside reverse transcriptase inhibitors for treatment of hiv |
| EP2125781A2 (en) * | 2006-12-20 | 2009-12-02 | Amgen Inc. | Substituted heterocycles and methods of use |
| RU2009140319A (ru) * | 2007-04-02 | 2011-05-10 | Палау Фарма С.А. (Es) | Производные пирролпиримидина |
| NZ580671A (en) * | 2007-04-16 | 2012-03-30 | Hutchison Medipharma Entpr Ltd | Pyrimidine derivatives |
| BRPI0810411B8 (pt) * | 2007-04-18 | 2021-05-25 | Pfizer Prod Inc | derivados de sulfonil amida para o tratamento de crescimento celular anormal, seu sos, bem como composição farmacêutica |
| WO2009022171A1 (en) * | 2007-08-13 | 2009-02-19 | Astrazeneca Ab | Pyridinyiioxy pyridines as alk5 inhibitors |
| EP2179992A1 (de) * | 2008-10-21 | 2010-04-28 | Bayer Schering Pharma Aktiengesellschaft | Sulfonsubstituierte Anlinopyrimidinderivative als CDK-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel |
| AR074209A1 (es) * | 2008-11-24 | 2010-12-29 | Boehringer Ingelheim Int | Derivados de pirimidina utiles para el tratamiento del cancer |
| DE102010014426A1 (de) * | 2010-04-01 | 2011-10-06 | Bayer Schering Pharma Aktiengesellschaft | Verwendung neuer pan-CDK-Inhibitoren zur Behandlung von Tumoren |
| CN103958482B (zh) * | 2011-11-29 | 2017-06-09 | 健泰科生物技术公司 | 作为lrrk2调节剂的氨基嘧啶衍生物 |
| NZ629830A (en) * | 2014-07-14 | 2015-12-24 | Signal Pharm Llc | Methods of treating a cancer using substituted pyrrolopyrimidine compounds, compositions thereof |
| CN110386901B (zh) * | 2018-04-23 | 2022-11-25 | 上海医药工业研究院 | 含磺酰苯胺嘧啶结构的化合物及其作为抗肿瘤药物的应用 |
| US12037323B2 (en) * | 2018-05-03 | 2024-07-16 | Bristol-Myers Squibb Company | Uracil derivatives as Mer-AXL inhibitors |
| WO2020205560A1 (en) * | 2019-03-29 | 2020-10-08 | Incyte Corporation | Sulfonylamide compounds as cdk2 inhibitors |
| JP2023515629A (ja) * | 2020-02-28 | 2023-04-13 | フォチョン・バイオサイエンシーズ・リミテッド | Ｃｄｋ２／４／６阻害剤としての化合物 |
| WO2022096473A1 (en) * | 2020-11-04 | 2022-05-12 | Umicore | A positive electrode active material for rechargeable batteries |
| KR20230127228A (ko) * | 2020-11-27 | 2023-08-31 | 올오리온 테라퓨틱스 인크. | 아미노헤테로아릴 키나아제 억제제 |
| CA3207392A1 (en) * | 2021-02-05 | 2022-08-11 | Xiaoxia Yan | Cdk inhibitor |
-
2021
- 2021-11-26 KR KR1020237021724A patent/KR20230127228A/ko active Pending
- 2021-11-26 EP EP21897121.6A patent/EP4251613A4/en active Pending
- 2021-11-26 CN CN202180079929.6A patent/CN116528869B/zh active Active
- 2021-11-26 AU AU2021385745A patent/AU2021385745C1/en active Active
- 2021-11-26 JP JP2023531615A patent/JP2024506116A/ja active Pending
- 2021-11-26 IL IL303237A patent/IL303237A/en unknown
- 2021-11-26 US US18/254,573 patent/US20240166635A1/en active Pending
- 2021-11-26 CA CA3202990A patent/CA3202990A1/en active Pending
- 2021-11-26 WO PCT/CN2021/133429 patent/WO2022111621A1/en not_active Ceased
-
2022
- 2022-11-23 AU AU2022397678A patent/AU2022397678A1/en active Pending
- 2022-11-23 WO PCT/CN2022/133770 patent/WO2023093769A1/en not_active Ceased
- 2022-11-23 JP JP2024531423A patent/JP2024541533A/ja active Pending
- 2022-11-23 MX MX2024006300A patent/MX2024006300A/es unknown
- 2022-11-23 EP EP22897852.4A patent/EP4436959A4/en active Pending
- 2022-11-23 CN CN202280077473.4A patent/CN118475562A/zh active Pending
- 2022-11-23 CA CA3238970A patent/CA3238970A1/en active Pending
-
2024
- 2024-05-21 US US18/670,469 patent/US20250002480A1/en active Pending
-
2025
- 2025-01-02 AU AU2025200001A patent/AU2025200001A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2025160318A5 (https=) | ||
| RU2018138828A (ru) | Уменьшение массы опухоли путем введения ccr1 антагонистов в комбинации с pd-1 ингибиторами или pd-l1 ингибиторами | |
| JP2013506715A5 (https=) | ||
| JPWO2022002102A5 (https=) | ||
| JP2020533347A5 (https=) | ||
| JP2016513660A5 (https=) | ||
| JPWO2020236940A5 (https=) | ||
| JP2005505618A5 (https=) | ||
| JP2010509284A5 (https=) | ||
| EP2651927A1 (en) | Anti-viral compounds | |
| JP2020535144A5 (https=) | ||
| JP2020531593A5 (https=) | ||
| RU2011133128A (ru) | Противоопухолевые соединения дигидропиран-2-она | |
| JPWO2022111621A5 (https=) | ||
| JP2010515693A5 (https=) | ||
| JPWO2019214634A5 (https=) | ||
| JPWO2020165834A5 (https=) | ||
| JP2006522824A5 (https=) | ||
| CN116730979A (zh) | 一种Polθ抑制剂 | |
| WO2007042912A3 (en) | Heterocyclic compounds as pstat3/il-6 inhibitors | |
| RU2006130686A (ru) | Новые пиперидины в качестве модуляторов хемокинов (ccr) | |
| JP2020519568A5 (https=) | ||
| JPWO2022079290A5 (https=) | ||
| RU2010120810A (ru) | Гидратированные кристаллические сложные эфиры камптотецина для лечения рака | |
| JP2008179567A (ja) | ピラジン誘導体を有効成分とする抗がん剤 |